Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders
Attovia Therapeutics’ biologic medicines could offer advantages over currently available immune disorder drugs, such as…
Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders
Attovia Therapeutics’ biologic medicines could offer advantages over currently available immune disorder drugs, such as Sanofi’s blockbuster medicine Dupixent. The IPO comes as Attovia looks to expand clinical development of its pipeline in 2027. The post Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders appeared first on MedCity…
The Sleep Crisis We May Be Missing: Why Millions of Americans Remain Undiagnosed
Despite the silk masks, oils, and sleepy girl mocktails swirling around social media, one of the greatest causes of non-restorative sleep is rarely mentioned by wellness influencers online: actual sleep disorders. The post The Sleep Crisis We May Be Missing: Why Millions of Americans Remain Undiagnosed appeared first on MedCity News.
The Healthcare Leaders Driving Change Need to Get Better at Explaining It
Healthcare leaders who shape that future need more than innovation. They need a visible, credible voice that helps the people around them — patients, clinicians, employees, partners, and investors — understand what the change is, why it matters, and why this is the right person to lead it. The post The Healthcare Leaders Driving Change…
Pediatricians and Health Departments Sidestep Trump’s CDC on Vaccine Guidance
AMHERST, Mass. — For the last 30 years, whenever pediatrician John Snyder wanted to find the most up-to-date research on treating young patients, he would turn to the Centers for Disease Control and Prevention. If he wanted to learn more about an outbreak of measles or hantavirus, he would pore over the weekly CDC report…
Baltimore Is Rethinking What It Means To Call 911 — And Who Responds
BALTIMORE — In March in a McDonald’s parking lot off a busy street, mental health clinician Michala Williams met a 38-year-old woman in a car. “So, you called the police for help?” Williams asked the woman, who was sobbing uncontrollably and said she sometimes thinks about harming herself. She told Williams she has children ranging…
Is Constructing Multi-generational “Healthy Homes” a Good Investment?
By MIKE MAGEE Two decades ago, I was heavily into health visioning. I learned quickly that it was relatively easy to predict what would happen, but much more difficult to accurately peg when it would happen. At the time, I promoted “7 Visions.” Health is Political. Home-Centered Health Care Reconnecting The Family Techmanity Lifespan Planning…
QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll
QuantHealth raised $45 million in Series B funding to expand its AI platform, which simulates clinical trials before they run and predicts patient outcomes for pharma companies. The startup is aiming to cut the industry’s 90% trial failure rate and speed up the timelines for effective drugs to reach the market. The post QuantHealth Snags…
How Policymakers Can Improve Obesity Treatment and Affordability, Per American College of Physicians
The American College of Physicians is urging policymakers to expand access to obesity treatment and healthy foods while investing in prevention and research. The post How Policymakers Can Improve Obesity Treatment and Affordability, Per American College of Physicians appeared first on MedCity News.
The Future of CDC HIV Prevention Funding for Community Organizations
Following reports that CDC is ending Community Based Organization (CBO) funding for HIV prevention, this analysis provides a snapshot of where, to whom, and at what level these community grants were distributed in the past grant cycle. We find community organizations stand to lose significant amounts of funding, especially those located in the south.
Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline. The post Pathos Picks Up Two Cancer Drugs Poised for…
